Cargando…

Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure

AIMS: Large outcome studies demonstrated a reduction of heart failure hospitalization or cardiovascular death in patients with chronic heart failure (CHF). The renin–angiotensin system (RAS) is a key player in fluid and sodium regulation. The classic angiotensin‐converting enzyme–angiotensin II–angi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bosch, Agnes, Poglitsch, Marko, Kannenkeril, Dennis, Kolwelter, Julie, Striepe, Kristina, Ott, Christian, Rauh, Manfred, Schiffer, Mario, Achenbach, Stephan, Schmieder, Roland E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192237/ https://www.ncbi.nlm.nih.gov/pubmed/36782339 http://dx.doi.org/10.1002/ehf2.14313

Ejemplares similares

Is vascular remodelling in patients with chronic heart failure exaggerated?
por: Pietschner, Robert, et al.
Publicado: (2022)

Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
por: Pietschner, R., et al.
Publicado: (2021)

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
por: Kolwelter, Julie, et al.
Publicado: (2021)

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
por: Ott, Christian, et al.
Publicado: (2021)

Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study
por: Kolwelter, Julie, et al.
Publicado: (2022)

Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction
por: Jung, Susanne, et al.
Publicado: (2021)

The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial
por: Kolwelter, Julie, et al.
Publicado: (2022)

Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a cross sectional analysis
por: Staef, Mawadah, et al.
Publicado: (2023)

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
por: Bosch, Agnes, et al.
Publicado: (2019)

Hypertrophic remodelling of retinal arterioles in patients with congestive heart failure
por: Jung, Susanne, et al.
Publicado: (2021)

Early vascular parameters in the micro- and macrocirculation in type 2 diabetes
por: Kannenkeril, Dennis, et al.
Publicado: (2018)

Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography
por: Jung, Susanne, et al.
Publicado: (2020)

Retinal Capillary Rarefaction in Patients with Type 2 Diabetes Mellitus
por: Jumar, Agnes, et al.
Publicado: (2016)

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
por: Ott, Christian, et al.
Publicado: (2017)

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
por: Karg, M. V., et al.
Publicado: (2018)

Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers
por: Gessner, Arne, et al.
Publicado: (2022)

Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
por: Arendse, Lauren B., et al.
Publicado: (2019)

Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System in L-NAME-Induced Hypertension
por: Simko, Fedor, et al.
Publicado: (2018)

Effect of Melatonin on the Renin-Angiotensin-Aldosterone System in l-NAME-Induced Hypertension
por: Simko, Fedor, et al.
Publicado: (2018)

Editorial comment: Renal denervation
por: Schmieder, Roland E., et al.
Publicado: (2021)

Effects of Endogenous Angiotensin II on Abdominal Aortic Aneurysms and Atherosclerosis in Angiotensin II–Infused Mice
por: Kukida, Masayoshi, et al.
Publicado: (2021)

Neurogenic tachykinin mechanisms in experimental nephritis of rats
por: Rodionova, Kristina, et al.
Publicado: (2020)

Afferent neurons of the kidney with impaired firing pattern in inflammation – role of sodium currents?
por: Lale, Nena, et al.
Publicado: (2023)

Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin-Angiotensin-System
por: Poglitsch, Marko, et al.
Publicado: (2012)

Molecular remodeling of the renin-angiotensin system after kidney transplantation
por: Antlanger, Marlies, et al.
Publicado: (2017)

Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England
por: Kolovos, Spyros, et al.
Publicado: (2023)

Neurogenic substance P—influences on action potential production in afferent neurons of the kidney?
por: Rodionova, Kristina, et al.
Publicado: (2021)

Myocardial infarction with a preserved ejection fraction—the impaired function of the cardio-renal baroreflex
por: Pickny, Lisa, et al.
Publicado: (2023)

Aldosterone and cortisol synthesis regulation by angiotensin-(1-7) and angiotensin-converting enzyme 2 in the human adrenal cortex
por: Caroccia, Brasilina, et al.
Publicado: (2021)

Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%
por: Kolovos, Spyros, et al.
Publicado: (2023)

Empagliflozin—A New Chance for Patients with Chronic Heart Failure
por: Kowalska, Klaudia, et al.
Publicado: (2021)

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
por: Biegus, Jan, et al.
Publicado: (2022)

Effects of Empagliflozin on Diuretics Reduction in Outpatient Heart Failure Patients
por: Kim, Soo-Jin, et al.
Publicado: (2022)

Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure
por: Gotzmann, Michael, et al.
Publicado: (2023)

Combined sodium glucose co‐transporter‐2 inhibitor and angiotensin‐converting enzyme inhibition upregulates the renin‐angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double‐blind, placebo‐controlled exploratory trial
por: Antlanger, Marlies, et al.
Publicado: (2022)

The Effect of FGF23 on Cardiac Hypertrophy Is Not Mediated by Systemic Renin-Angiotensin- Aldosterone System in Hemodialysis
por: Dörr, Katharina, et al.
Publicado: (2022)

The systemic and hepatic alternative renin–angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation
por: Hartl, Lukas, et al.
Publicado: (2023)

Empagliflozin Alleviates Left Ventricle Hypertrophy in High-Fat-Fed Mice by Modulating Renin Angiotensin Pathway
por: Cotrin, Juliana Cordovil, et al.
Publicado: (2022)

Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study
por: Kovarik, Johannes J., et al.
Publicado: (2021)

A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
por: Tafazzoli, Ali, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rue0ccrfbik6tqs5rpbj2l0cmu